Tedatioxetine

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameTedatioxetine
Drug Alias Nametedatioxetina替达西汀特硫西汀tedatioxetinumTedatioxetine hydrobromide +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2c (5-HT2c) receptor antagonistsSerotonin 3 (5-HT3) receptor antagonists
TargetsSerotonin 2c (5-HT2c) receptorSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co LtdH. Lundbeck A/S
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, Major

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG